Skip to main content
Fig. 1 | Acta Neuropathologica Communications

Fig. 1

From: Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans

Fig. 1

In vivo efficacy of tau antibody DC8E8 targeting microtubule binding domain in the brains of transgenic mice. a Biochemical quantification of sarkosyl-insoluble tau protein extracts (2p) isolated from brainstem of transgenic mice treated with irrelevant control DC51 (n = 17) vs immunotherapeutic DC8E8 antibody (n = 12) evaluated using sandwich AT8/DC190 HRP ELISA. Data are presented as mean ± SEM. p* ≤ 0.01 with statistically significant reduction in the induction of tau pathology in DC8E8 treated animals in comparison to animals treated with control antibody. b Quantitative immunohistochemistry of mouse brain tissue samples. Neurofibrillary tangles were counted in two parallel sections of the brainstem from each mouse (control n = 18, DC8E8 n = 18). Quantification of AT8-positive NFTs was carried out by investigators blinded to the treatment status of the mice. Data are presented as mean ± SEM. p** = 0.0054 with statistically significant reduction in the formation of NFTs in DC8E8 treated animals in comparison to animals treated with control antibody DC51. c Representative images of pathological structures consistent with neurofibrillary tangles (NFTs) positive for AT8 immunohistochemical staining in transgenic mice R3m4 expressing human truncated tau (151–391/3R) treated with irrelevant control (DC51) or DC8E8 antibody. AT8 immunostaining was robustly decreased in mice after immunization with DC8E8 antibody in comparison to control antibody. Scale bars: 200 μm; right panel 20 μm

Back to article page